Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Companies / Egypt

BMS Bails On Risky Markets

October 2008 | Company News Alert

US-based Bristol-Myers Squibb (BMS)'s decision to reduce its exposure to two of the most challenging emerging markets suggests that it has lost its appetite for risk. BMS has sold its Egyptian mature products business to GlaxoSmithKline (GSK) for US$210mn. Meanwhile, Pakistan's Daily Times has quoted 'well-informed sources' within Pakistan's pharmaceutical industry that have seen confidential papers circulated by BMS, which state that the company is seeking a buyer for its local

Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.

[
: *
[
: *


If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.

If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.

Free Trial To Pharmaceuticals & Healthcare Insight

TAKE A TRIAL >>
Middle East & Africa InsightMiddle East & Africa Channels Middle East & Africa Countries